GST Refund for Pharma Exporters

The Indian pharmaceutical industry is the world's third-largest by volume and the largest provider of generic medicines globally - covering bulk drugs (Active Pharmaceutical Ingredients or APIs), formulations, biologics and biosimilars, vaccines, medical devices, nutraceuticals, and ayurvedic preparations. Major manufacturing clusters include Hyderabad and Visakhapatnam (bulk drug hubs accounting for over 40 percent of national API production), Ahmedabad-Vatva-Ankleshwar-Vapi (intermediates and APIs), Mumbai-Tarapur (formulations and biologics), Sikkim/HP/Uttarakhand (formulation excise zones), Pune-Goa (Sun Pharma, Lupin, Cipla), Chennai-Hosur (formulations and CMO), and Bengaluru (biotech and biosimilars). The sector exports to over 200 countries and serves international tenders from WHO procurement, Global Fund, Gavi, UNICEF, PEPFAR, and foreign Ministry of Health bilateral arrangements.

GST refund opportunities span 6 distinct revenue routes - LUT goods exports under Rule 96A, IGST-paid goods exports under Rule 96, inverted duty structure (IDS) API-to-formulation under Rule 89(5) with Statement 1A (dominant cash route post the 56th GST Council recommendation effective 22 September 2025), IDS bulk-drug-to-formulation for integrated manufacturers, deemed exports under EOU and Advance Authorisation per Notification 48/2017-CT and Notification 49/2017-CT, and international tender supplies (UN, Global Fund, Gavi, UNICEF, PEPFAR). The widened IDS gap from 6 to 13 percentage points (18 percent on APIs to 5 percent on formulations post GST 2.0) more than doubles ITC accumulation for typical formulation manufacturers. CGST Instruction 6/2025 dated 3 October 2025 layers 90 percent provisional refund within 7 days of RFD-02 onto this larger refund pool - Patron Accounting LLP serves 50+ active pharma clients across all major clusters.

Content is reviewed quarterly for accuracy.

The service applies to Indian pharma manufacturers and exporters across 7 major manufacturing clusters and 6 distinct revenue routes. Each cluster has dominant route profile.

• Hyderabad and Vizag (Telangana, Andhra Pradesh) - bulk drug / API hub accounting for over 40 percent of national API production; dominant routes - LUT API exports (Route 1), IDS where formulation arm exists (Route 3 and 4); quarterly Rs 50 lakh to Rs 5 crore typical
• Ahmedabad / Vatva / Ankleshwar / Vapi (Gujarat) - intermediates, API, agrochemicals overlap; dominant routes - LUT exports (Route 1), deemed exports to EOU formulation manufacturers (Route 5); quarterly Rs 30 lakh to Rs 3 crore typical
• Mumbai / Tarapur / Boisar (Maharashtra) - formulations, biologics, vaccines; dominant routes - LUT formulation exports (Route 1), IDS (Route 3), international tenders (Route 6); quarterly Rs 25 lakh to Rs 4 crore typical
• Sikkim / Himachal Pradesh / Uttarakhand (Northern excise zones) - formulations in legacy excise zone manufacturing units; significant IDS post GST 2.0; quarterly Rs 15 lakh to Rs 1.5 crore typical
• Pune / Goa (Maharashtra, Goa) - formulations with Sun Pharma, Lupin, Cipla anchors; premium branded generic exports plus major Global Fund and Gavi suppliers; quarterly Rs 30 lakh to Rs 5 crore typical
• Chennai / Hosur (Tamil Nadu) - formulations, biotech, contract manufacturing; mid-size formulation exports with CMO arrangements; quarterly Rs 20 lakh to Rs 2 crore typical
• Bengaluru (Karnataka) - biotech, biosimilars, vaccines; biosimilar and vaccine exports with UN procurement as major channel; quarterly Rs 25 lakh to Rs 3 crore typical

Threshold and pre-condition: GST registration is mandatory once aggregate turnover crosses Rs 40 lakh for goods suppliers (Rs 20 lakh in Special Category States) under Section 22 CGST Act. If the pharma manufacturer is not registered, complete GST registration before claiming refund. LUT (Form RFD-11) under Rule 96A is required for export without IGST. CDSCO Form 13 manufacturing licence under Drugs and Cosmetics Act 1940 read with Rules 1945 is required for valid manufacturing. CDSCO Form 28-D NOC is required for export of drugs not approved for use in India.

• GSTIN certificate of the pharma manufacturer or exporter
• Letter of Undertaking (Form GST RFD-11) acknowledgement under Rule 96A for the financial year (for LUT routes)
• CDSCO Form 13 manufacturing licence under Drugs and Cosmetics Act 1940 read with Rules 1945
• CDSCO Form 9 wholesale licence (where applicable for stocking and distribution)
• CDSCO Form 28-D export NOC for drugs not approved for use in India (via SUGAM portal)
• Certificate of Pharmaceutical Product (CoPP) in WHO format for international tender supplies and unapproved-in-India exports
• WHO-GMP certification (currency check annually)
• Free Sale Certificate (FSC) confirming product is freely sold in India
• Tax invoice with HSN code per Schedule I (5%) or Schedule III (18%) of Notification 1/2017-CT(R) post GST 2.0
• Shipping bill, BRC (Bank Realisation Certificate), and EGM (Export General Manifest) for goods exports
• FIRC (Foreign Inward Remittance Certificate) with BSR code for international tender supplies
• GSTR-1, GSTR-3B (Table 6A for exports), and GSTR-2B for the refund period
• Statement 1A under Rule 89(2)(h) for IDS; Statement 3 under Rule 89(2)(b) for goods exports; Statement 5/5A/5B under Rule 89(2)(g) for deemed exports
• HSN-rate reconciliation working sheet matching inputs and outputs against Schedule I/III
• For deemed exports - Form A intimation, Form B receipt evidence under Notification 49/2017-CT
• For international tenders - tender award letter, country-specific export certifications, structured invoice per tender terms
• CA certificate in Annexure 2 of RFD-01 where refund exceeds Rs 2 lakh
• Net ITC working sheet - Rule 89(4) for LUT exports (inputs + services); Rule 89(5) for IDS (inputs only post VKC Footsteps SC 2021)

Worked Example - Hyderabad Integrated Pharma Manufacturer Multi-Route Refund

All fees and charges listed are indicative only and do not constitute a binding offer. Final amounts may vary depending on the volume of work and the complexity involved.

Professional service charges for drafting, filing, and representation are separate from the statutory fees. The exact fee depends on the complexity of the case, disputed amount, and number of hearings required. Contact us for a detailed quote.

Get a free Pharma Exporter Refund consultation - Call +91 945 945 6700 or WhatsApp us. No-obligation assessment.

10,000+ Businesses | 4.9 Google Rating | 50,000+ Documents Filed | 15+ Years of Pharma Sector GST Compliance Experience

Trusted By

Hyundai, Asian Paints, Bridgestone, and 50+ Indian pharmaceutical exporters including Hyderabad bulk drug manufacturers, Vizag API producers, Ahmedabad intermediate suppliers, Mumbai formulation exporters, Sikkim/HP/Uttarakhand excise zone manufacturers, Pune/Goa branded generic exporters, Chennai/Hosur formulation makers, and Bengaluru biotech and biosimilar firms with active multi-route GST refund pipelines handled by Patron Accounting LLP.

Outcome Proof

A Hyderabad integrated pharma manufacturer recovered Rs 4.5 crore quarterly multi-route refund in March 2026 across 5 routes - LUT formulation exports Rs 1.6 crore, IGST exports Rs 35 lakh, IDS API-to-formulation Rs 1.4 crore (more than doubled post GST 2.0 from pre-22.09.2025 estimate of Rs 65 lakh), deemed exports to EOU formulation manufacturer Rs 90 lakh, and Global Fund tender supply of antiretrovirals Rs 25 lakh. Provisional 90 percent Rs 4.05 crore disbursed within 22 days of ARN under CGST Instruction 6/2025; balance Rs 45 lakh within 50 days. Multi-route Form RFD-01 filings with Statement 1A, 3, 5 - all accepted on first attempt. CDSCO documentation parallel coordination ensured zero export shipment delay.

With offices in Pune, Mumbai, Delhi, and Gurugram, Patron Accounting serves pharma manufacturers across India - both in-person and remotely.

Pharma exporter refund work integrates with the broader GST refund and compliance stack. Most pharma manufacturers need adjacent compliance running in parallel:

• GST Refund - parent practice covering all Section 54 refund categories beyond pharma exports such as excess balance, tax paid in error, or appeal-related refunds
• GST Returns - monthly GSTR-1 (Table 6A for exports) and GSTR-3B (Table 3.1(b)) that anchor every pharma refund claim across all 6 routes
• GST Annual Returns - GSTR-9 and GSTR-9C reconciliation that must precede any refund audit in a financial year
• GST Audit - for pharma exporters above the prescribed turnover threshold; departmental GSTR-9C reconciliation; pre-audit documentation pack
• GST Registration - mandatory under Section 22 CGST Act once aggregate turnover crosses Rs 40 lakh for goods (Rs 20 lakh in Special Category States)
• GSTAT Appeal - Exporters - escalation route when Section 107 appeal on pharma refund rejection is adverse; pre-deposit and grounds preparation for HSN classification, VKC Footsteps Net ITC, deemed export disputes

Section 16 of IGST Act 2017 - Zero-Rated Supply

(1) 'Zero-rated supply' means export of goods or services or both, or supply for authorised operations to SEZ developer or unit. (3) A registered person making zero-rated supply may claim refund under either of two options - (a) supply under LUT/bond without payment of IGST and claim refund of unutilised ITC; or (b) supply on payment of IGST and claim refund of IGST paid. Pharma exporters typically use option (a) LUT for high-ITC scenarios and option (b) IGST for niche cases.

Section 54(3) of CGST Act 2017 - Refund of Accumulated ITC

A registered person may claim refund of any unutilised input tax credit at the end of any tax period. Refund of unutilised ITC shall be allowed only in cases of - (i) zero-rated supplies made without payment of tax; or (ii) where credit has accumulated on account of rate of tax on inputs being higher than rate of tax on output supplies (other than nil-rated or fully exempt supplies). Pharma exporters invoke clause (i) for LUT exports (Routes 1 and 6) and clause (ii) for IDS API-to-formulation (Routes 3 and 4).

56th GST Council Recommendation (3 September 2025) - GST 2.0 Pharma Rate Rationalisation

The GST Council at its 56th meeting recommended sweeping rate rationalisation effective 22 September 2025. For pharmaceuticals - most formulations under HSN 3003 and 3004 moved from 12 percent to 5 percent (Schedule I of Notification 1/2017-CT(R)); specified life-saving drugs moved to 0 percent (Nil); APIs under HSN 2941 and other categories maintained at 18 percent (Schedule III); excipients, packaging materials, and analytical services maintained at 18 percent. Industry impact - inverted duty structure gap for formulation manufacturers widened from 6 percentage points to 13 percentage points, increasing ITC accumulation and refund quantum significantly.

CGST Instruction 6/2025 dated 3 October 2025 - 90 Percent Provisional for Pharma

The Central Board of Indirect Taxes and Customs issued Instruction No. 6/2025-GST extending the 90 percent provisional refund framework under Notification 13/2025-Central Tax dated 17 September 2025 (effective 01 October 2025) to refund applications filed under the inverted duty structure category. Pharmaceutical sector is one of four priority sectors (textiles, chemicals, pharmaceuticals, fertilisers) with 7-day refund window. Low-risk applicants assessed under 8-factor risk audit are entitled to 90 percent provisional refund within 7 days of RFD-02 acknowledgement under Rule 91(2).

Rule 89(5) of CGST Rules 2017 - IDS Net ITC Formula

In case of refund on account of inverted duty structure, refund of input tax credit shall be granted as per the formula - Maximum Refund Amount = ((Turnover of inverted rated supply of goods and services) x Net ITC / Adjusted Total Turnover) minus tax payable on such inverted rated supply of goods and services x (Net ITC / ITC availed on inputs and input services). Per Notification 26/2018-CT and Union of India v VKC Footsteps India Pvt Ltd (Supreme Court, 2021), Net ITC is restricted to inputs only (excludes input services and capital goods).

Union of India v VKC Footsteps India Pvt Ltd (Supreme Court, 2021)

FOUNDATIONAL - The Supreme Court held that Rule 89(5) of CGST Rules 2017 as amended by Notification 26/2018-CT is intra vires and does not discriminate between inputs and input services. Refund of unutilised ITC under Section 54(3)(ii) for IDS is restricted to input goods only - excluding input services such as freight, R&D services, analytical charges, professional services, and capital goods. The judgment governs Net ITC computation for all IDS refunds across sectors including pharma.

Drugs and Cosmetics Act 1940 read with Drugs and Cosmetics Rules 1945 - CDSCO Framework

Pharma exports require parallel CDSCO regulatory compliance. Form 9 - wholesale licence for stocking and distribution. Form 13 - manufacturing licence for production. Form 28-D - export NOC for drugs not approved for use in India (tropical disease drugs, generics under foreign approval but not yet Indian); issued by Drugs Controller General of India through SUGAM portal. Form 26 - manufacturing licence in lieu of export for products meant exclusively for export markets. Certificate of Pharmaceutical Product (CoPP) - WHO-format export certification; typical validity 2 years. WHO-GMP certification - Good Manufacturing Practices compliance evidence. Free Sale Certificate (FSC). These documents do not directly affect GST refund computation but are required for valid export shipment.

Notification 48/2017-Central Tax - Deemed Exports Framework

The Central Government notified specified categories of supplies as deemed exports - (a) supply against Advance Authorisation; (b) supply of capital goods against EPCG Authorisation; (c) supply to Export Oriented Unit; (d) supply of gold by bank or PSU against AA. Pharma manufacturers commonly use category (a) and (c) - API supplier to EOU formulation manufacturer is typical pattern. Notification 49/2017-CT specifies conditions including supplier-recipient election for refund claim.

Notification 1/2017-CT(R) - Pharma Rate Schedule (As Amended Post 22.09.2025)

Schedule I (5 percent) covers most medicaments under HSN 3003 (multi-constituent) and HSN 3004 (measured doses or retail packing) post GST 2.0; specified ayurvedic, homeopathic, biochemic, unani medicines; menstrual hygiene products. Schedule III (18 percent) covers APIs and bulk drugs under HSN 2941 (antibiotics), specified entries under HSN 2933, 2934, 2935 (heterocyclic compounds and sulphonamides); excipients; medical equipment, and other categories. Pre-22.09.2025 the formulation rate was 12 percent under Schedule II (now repositioned).

Five statutory clocks run together for a pharma manufacturer/exporter. Miss any one and the consequences differ but each is material:

• LUT FY 2026-27 renewal - before 31 March 2026 (or first export of FY 2026-27); every export from 1 April 2026 attracts IGST upfront if LUT not on record under Rule 96A
• 2-year refund limitation under Section 54(1) - counted from relevant date (typically end of FY); statutory bar; no condonation under Section 54
• 9-month FEMA window for FX realisation - RBI Master Direction on Export of Goods and Services; without timely realisation or RBI extension, refund eligibility lapses
• CDSCO Form 28-D pre-shipment - for drugs not approved for use in India; customs hold if missed; shipping delay cascades into GST refund cycle
• CoPP renewal - every 2 years typical; validity expiry blocks tender participation
• WHO-GMP currency check - annual; tender disqualification if expired
• RFD-02 acknowledgement - within 15 days of ARN under Rule 90(2); escalate via grievance if officer fails
• RFD-04 provisional 90 percent - within 7 days of RFD-02 for low-risk pharma applicants under CGST Instruction 6/2025 effective 01.10.2025
• RFD-06 final sanction - within 60 days of RFD-02 under Section 54(7); 6 percent Section 56 interest if delayed; 9 percent for appellate orders
• Section 107 appeal - within 3 months of RFD-06; +1 month condonable under Section 107(4); 10 percent pre-deposit

Engage Patron Accounting for pharma exporter compliance retainer - share GSTIN, primary product mix (API/formulation/biologic), export markets, monthly turnover, and cluster location. Call +91 945 945 6700 or WhatsApp us now.

Indian pharmaceutical exporters operate across 6 distinct GST refund routes - LUT goods exports under Rule 96A, IGST-paid exports under Rule 96, IDS API-to-formulation under Rule 89(5) post the widened 22.09.2025 gap, IDS bulk-drug-to-formulation for integrated manufacturers, deemed exports under EOU and Advance Authorisation per Notification 48/2017-CT and Notification 49/2017-CT, and international tender supplies to UN procurement, Global Fund (HIV/TB/malaria), Gavi (vaccines), UNICEF, PEPFAR, and foreign Ministry of Health bilateral arrangements.

The 56th GST Council meeting on 3 September 2025 recommended GST 2.0 rate rationalisation effective 22 September 2025 - moving most formulations under HSN 3003 and 3004 from 12 percent to 5 percent under Schedule I of Notification 1/2017-CT(R) while leaving APIs under HSN 2941 and other categories at 18 percent under Schedule III. This widened the inverted duty structure gap from 6 percentage points to 13 percentage points - dramatically increasing ITC accumulation. CGST Instruction 6/2025 dated 3 October 2025 (read with Notification 13/2025-CT) extended the 90 percent provisional refund framework within 7 days of RFD-02 to IDS - identifying pharma as one of 4 priority sectors with accelerated processing. Net ITC under Rule 89(5) is restricted to inputs only post Union of India v VKC Footsteps India Pvt Ltd Supreme Court 2021. Parallel CDSCO documentation under Drugs and Cosmetics Act 1940 read with Rules 1945 includes Form 9, Form 13, Form 28-D, CoPP in WHO format, WHO-GMP, and FSC.

Patron Accounting LLP brings 15+ years of pharma sector GST refund experience covering all 6 revenue routes, GST 2.0 rate rationalisation impact analysis (22.09.2025), CGST Instruction 6/2025 risk-based provisional refund optimisation, CDSCO export documentation coordination through SUGAM portal, international tender procurement frameworks (UN, Global Fund, Gavi, UNICEF, PEPFAR), deemed export coordination under EOU and Advance Authorisation, 7-cluster pharma refund optimisation across Hyderabad/Vizag bulk drug hubs, Ahmedabad/Ankleshwar/Vapi intermediates, Mumbai/Tarapur formulations, Sikkim/HP/Uttarakhand excise zones, Pune/Goa branded generic formulations, Chennai/Hosur formulations, and Bengaluru biotech and biosimilars, VKC Footsteps SC 2021 Net ITC discipline, and Section 107 appeal experience for 50+ active pharma exporter clients with four physical offices in Pune, Mumbai, Delhi, and Gurugram.